Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (40)
NITAG documentation (1618)
Reports (60)
SAGE documentation (226)
Scientific publications (117)
Systematic reviews (SYSVAC) (2936)
Regions
Africa (289)
Americas (776)
Eastern Mediterranean (53)
Europe (726)
Global (1)
South-East Asia (82)
Western Pacific (210)
Diseases
Chikungunya (11)
Cholera (35)
COVID-19 (1545)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (81)
Ebola (17)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (162)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (508)
Influenza (605)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (30)
Measles (137)
Meningococcal disease (150)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (109)
Pneumococcal disease (287)
Poliomyelitis (88)
Q fever (1)
Rabies (31)
Rotavirus (118)
RSV (Respiratory syncytial virus) (57)
Rubella (65)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (62)
Tick-borne encephalitis (12)
Tuberculosis (78)
Typhoid (27)
Varicella (74)
Yellow fever (43)
Zika (1)
Show more
4997 results found
2015
∙
SAGE
Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a single-dose MenA conjugate vaccination in immunocompetent children (9 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a two dose schedule of MenA conjugate vaccination in immunocompetent children (3 to 9 months of age) against serogroup A meningococcal disease
2015
∙
CoNaIn
National Immunization Schedule (Argentina)
2015
∙
SAGE
Pertussis Vaccine Evidence to Recommendations Table
2015
∙
SAGE
Protective Efficacy/Effectiveness of Whole Cell Pertussis Vaccines (wP) in Immunocompetent Infants and Children
2015
∙
SAGE
Safety of MenA conjugate vaccination in immunocompetent children (3 to 24 months of age)
2015
∙
OFSP
Swiss 2015 vaccination plan
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live recombinant JE vaccine?
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register